SCHEMBL5773780

SCHEMBL5773780

CSc1ccc(-c2cc(Cl)cnc2O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 1/20 0.37
GSK3B P49841 1/20 0.37
PTGS2 P35354 8/20 0.36
PTGS1 P23219 4/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
WEE1 P30291 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CHRNA7 P36544 1/20 0.36
ABCC4 O15439 1/20 0.35
ABCB11 O95342 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775335 0.83 GSK3B (0.38) ALDH1A1KMT2AMEN1HTTL3MBTL1
SCHEMBL5904269 0.77 NPSR1 (0.49) KMT2AMEN1HTTMAPTGAA
SCHEMBL6069906 0.75 PTGS2 (0.63) PTGS2PTGS1ABCC4ABCB11PDE4D
SCHEMBL5774670 0.75 PTGS2 (0.64) PTGS2PTGS1CHRNA7ABCC4ABCB11
SCHEMBL28631630 0.75 MAP4K4 (0.47) PTGS2PTGS1CHRNA7
SCHEMBL4027051 0.73 PTGS2 (0.66) PTGS2PTGS1ABCC4ABCB11PDE4D
SCHEMBL5772476 0.71 SLC6A4 (0.46)
SCHEMBL28147339 0.71 FFAR4 (0.37) PTGS2PTGS1ABCC4ABCB11PDE4D
SCHEMBL5989061 0.70 CYP2A6 (0.50) ALDH1A1L3MBTL1KDM4EPTGS2PTGS1
SCHEMBL8802559 0.69 ALOX5 (0.42) ALDH1A1KMT2AMEN1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104788362-A Preparation method of etoricoxib or pharmaceutically acceptable salts thereof JINAN SANYUAN CHEMICAL CO LTD 2015-07-22 CN disclosed
US-20060229338-A1 2,3'-bipyridines derivatives as selective cox-2 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-10-12 US disclosed
EP-1592666-A1 2,3 -BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-11-09 EP disclosed
WO-2004072037-A1 2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS ALMIRALL PRODESFARMA S.A. (ES) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229338-A1 2,3'-bipyridines derivatives as selective cox-2 inhibitors PTGS2, PTGES2, PTGER2 ALDH1A1 407/4885KMT2A 3501/4885MEN1 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.